LOS ANGELES, May 10, 2024 (GLOBE NEWSWIRE) — ACTG, a global clinical trials network focused on HIV and other infectious diseases, today announced the publication of results from SLIM LIVER (also known as A5371) in the Annals of Internal Medicin
LOS ANGELES, May 10, 2024 (GLOBE NEWSWIRE) -- ACTG, a global clinical trials network focused on HIV and other infectious diseases, today announced the publication of results from SLIM LIVER (also known as A5371) in the Annals of Internal Medicine. “The Effect of Open-Label Semaglutide on Metabolic Dysfunction–Associated Steatotic Liver Disease in People With HIV” demonstrates that semaglutide was highly effective in improving, and in some cases, resolving completely, metabolic dysfunction-associated steatotic liver disease (MASLD, formerly known as non-alcoholic fatty liver disease) among people living with HIV. Read More